Общие вопросы / Хосева 2014 Диссертация

291

153. Федеральная служба по надзору в сфере здравоохранения_Международное сотрудничество// URL: http://www.roszdravnadzor.ru/aboutfederal/international_act/info

154. Хабриев, Р.У. Руководство по экспериментальному (доклиническому) изу-

чению новых фармакологических веществ / Под ред. Р.У. Хабриева. – 2-е изд. – М.: Медицина, 2005.

155.Холн, Т.А. Регулирование фармацевтического рынка: существует ли почва для развития инновационных фармацевтических препаратов в России? / Т.А. Холн //Проблемы учета и финансов. - 2012. – №4 (8) - С. 73-75.

156.Хубиева, М. Ю. Проблемы качества и терапевтической эквивалентности дженериков[Электронный ресурс] / М.Ю. Хубиева, Н.В. Юргель, Е.А. Ушкалова, А.А. Малин,А.Ю. Хубиева //Здравоохранение. - 2010. - №11.- Режим доступа:

http://www.mcfr.ru/journals/1/252/30637/

157. Хубиева, М.Ю. Развитие системы фармаконадзора в ЗАО «ФП «Оболенское» [Электронный ресурс] / М.Ю. Хубиева. - Режим доступа: http://www.fru.ru/Phe/phe_pre_2011/1_march/RossLek/Hubieva%20MU.pdf

158.Хубиева, М.Ю. Актуальные проблемы мониторинга эффективности и безопасности медицинской продукции в Российской Федерации / М.Ю. Хубиева,А.М. Власов, С.В. Глаголев и соавт. // Вестник Росздравнадзора. – 2010. - №2. – С. 29-41.

159.Цветов, В.М. Знания фармацевтов вопросов побочных действий лекарств / В.М. Цветов, Г.Г. Кетова // Рациональное использование лекарств: материалы Рос.науч. – практ. конф. – Пермь. - 2004. - С. 352 – 353.

160.Цветов, В.М.Уровень знаний о неблагоприятном побочном действии лекарств / В.М. Цветов, Г.Г. Кетова// Актуальные вопросы клинической и экспериментальной медицины: материалы науч. – практ. конф. молодых ученых.

– СПб. - 2004. - С. 88.

161.Цветов, В. М. Мониторинг неблагоприятных побочных реакций лекарственных препаратов в амбулаторно-поликлиническом учреждении на

292

современном этапе: дис. ... канд. мед. наук: 14.00.25/Цветов Виталий Михайлович.

- Челяб., 2007. - 148 с.

162. ЦЭБЛС. Основные задачи центра экспертизы безопасности лекарственных средств [Электронный ресурс]. -Режим доступа: http://www.regmed.ru/fnz/Default.aspx

163.Шабров, Р.В. Закон «Об обращении лекарственных средств»: обзор и анализ изменений / Р.В. Шабров, А.Д. Шадрин // Ремедиум. – 2013. - №12 (202). – С. 6- 13.

164.Шальнова, С.А.Российские клинические исследования в каридиологии. Вчера, сегодня, завтра / С.А. Шальнова, С.Ю. Марцевич // Рациональная Фармакотерапия в Кардиологии. - 2010. - №6. - С. 434 - 437.

165.Шальнова, С.А. Российские клинические и эпидемиологические исследования в кардиологии / С.А. Шальнова, С.Ю. Марцевич, С.Н. Толпыгина, Е.В. Платонова. - Справочник. Выпуск 1. - М., 2010. - 130 с.

166.Широкова, И. От импортозамещения до инноваций / И. Широкова // Ремедиум. – 2011. - №8. – С. 72-73.

167.Шибалко, А.Н. Особенности российской практики формирования и развития фармацевтических кластеров / А.Н. Шибалко // Проблемы современной экономики. – 2012.- №4 (44), – С. 341 – 343.

168.Широкова, И. Строительство фармкластеров / И. Широкова // Ремедиум. - 2013. - №2 (192). – С. 24-31.

169.Эдлинский, И.Б. Мнение пациентов как важное направление улучшения системы обеспечения качественной медицинской помощью / И.Б. Эдлинский, А.Г. Рязанцева, И.Н. Капустина //В мире научных открытий. - 2010. - №4 (10). -

Часть 14. - С. 65-66.

170. Юргель, Н.В. Основные направления государственного регулирования фармрынка в современных условиях / Н.В. Юргель // Вестник Росздравнадзора.

2008. - №1. – С. 4-7.

293

171.Юргель, Н.В. Система надзора и контроля в сфере обращения лекарственных средств в Российской Федерации / Н.В. Юргель // Вестник Росздравнадзора. - 2008. - №6. – С.4-11.

172.Юргель, Н.В. Профилактика неблагоприятных побочных реакций: врачебная тактика рационального выбора применения лекарственных средств: руководство / под ред. Н.В. Юргеля, В.Г. Кукеса. – М.: ГЭОТАР – Медиа, 2009. – 448 с. (Библиотека врача специалиста).

173.Юргель, Н.В. Состояние фармацевтического рынка Российской Федерации и воздействие на него мирового финансового и экономического кризиса / Н.В. Юргель, Е.А. Тельнова //Вестник Росздравнадзора. - 2009.- №1. – С.46-56.

174.Юргель, Н.В. Система фармаконадзора в Российской Федерации: итоги 2009 г. / Н.В. Юргель, М. Ю. Хубиева, Е.А. Ушкалова и соавт. // Вестн. Росздравнадзора.- 2010. - №2. – С. 20-28.

175.Юргель, Н.В. Приоритеты государственного регулирования в условиях стабильного фармацевтического рынка / Н.В. Юргель // Ремедиум. – 2008. - №1. – С. 32-35.

176.Якусевич, В.В. Оценка качества препаратов-дженериков в кардиологии: реалии и возможности / В.В. Якусевич // Рациональная фармакотерапия в кардиологии. - 2005. - № 1. - С.13-18.

177.Якусевич, В.В. Качественное лекарственное средство: каким оно должно быть / В.В. Якусевич // Рациональная фармакотерапия в кардиологии. - 2006. - №4. С.41-46.

178.Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish Adverse Drug Reaction Database from 2004 to 2006. Drug Saf 2009; 32: 1067–74.

179.Aagaard L, Hansen EH. (2010) Consumers' reports of suspected adverse drug reactions volunteered to a consumer magazine. Br J Clin Pharmacol.69:3 317-318. doi:10.1111/j.1365-2125. 2009.03584.x

180.Agrawal A. Medication errors: prevention using information technology systems. Br J Clin Pharmacol 2009; 67: 681–6.

294

181.Anne Decollogny, Yves Eggli, Patricia Halfon, and Thomas M Lufkin Determinants of generic drug substitution in Switzerland BMC Health Serv Res. 2011; 11: 17.

182.Alan G Wade, Gordon M Crawford, Neil Pumford, Volker Koscielny, Susan Maycock, Alex McConnachie. Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation. BMC Medical Research Methodology 2011, 11:91

183.Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Med Care. 2009 Mar;47(3):319-25.

184.Approved Drug Products with Therapeutic Equivalence Evaluations. Federal Drug

Administration; 2010. [Электронныйресурс]. - Режимдоступа:

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Gui

dances/ucm070636.pdf

185. A. Vallano, C. Pedrós, A. Agustí, G. Cereza, I. Danés, C. Aguilera, J. Maria Arnau. Educational sessions in pharmacovigilance: What do the doctors think?BMC Research Notes 2010, 3:311 doi:10.1186/1756-0500-3-311.

186.Backstrom M, Mjorndal T, Dahlqvist R, et al. Attitudes to reporting adverse drug reactions in northern Sweden. Eur J Clin Pharmacol. 2000;56:729–732. doi: 10.1007/s002280000202.

187.Bäckström M, Mjörndal T, Dahlqvist R. Spontaneous reporting of adverse drug

reactions by nurses. Pharmacoepidemiol Drug Saf. 2002;11:647–650. doi: 10.1002/pds.753.

188.Baniasadi S, Fahimi F, Shalviri G. Developing an adverse drug reaction reporting system at a teaching hospital. Basic Clin Pharmacol Toxicol. 2008;102:408–11. doi: 10.1111/j.1742-7843.2008.00217.x.

189.Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl JMed 362:865–869. doi:10.1056/NEJMp0911494

295

190.Bencheikh RS, Benabdallah G.Medication errors: pharmacovigilance centres in detection and prevention. Br J Clin Pharmacol 2009; 67: 687–90.179.

191.Blenkinsopp A, Wilkie P.,Wang M. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2006;63;148-56.doi:10.1111/j.1365-2125.2006.02746.x.

192.Belton KJ, Lewis SC, Payne S, et al. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol. 1995;39:223–226.

193.Bracchi RC, Houghton J, Woods FJ, Thomas S, Smail SA, Routledge PA. A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme. Br J Clin Pharmacol. 2005;60:221–223. doi: 10.1111/j.13652125.2005.02419.x.

194.Britten N. Medication errors: the role of the patient. Br J Clin Pharmacol 2009; 67: 646–50.

195.Communicating about potential drug harms: safety implications for patients Br J Clin Pharmacol / 68:2 / 147–148.

196.Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigations in Children. Br Med J. 2000;320:79-82.

197.Cheung K-C, Bouvy ML, De Smet PAGM. Medication errors: the importance of safe dispensing. Br J Clin Pharmacol 2009;67: 676–80.

198.Chopra D., Wardhan N., Rehan H.S. Knowledge, attitude and practices associated with adverse drug reaction reporting amongst doctors in a teaching hospital. Int J. Risk Saf Med. 2011; 23(4):227-32.

199.de Langen J, van Hunsel F, Passier A et al (2008) Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf 31:515–524. doi:10.2165/00002018-200831060-00006

296

200.Danish Medicines Agency. One Year with ADR Consumer Reports. October 2004. Available at http://www.dkma.dk/1024/ visUKLSArtikel.asp?artikelID= 4710 (last accessed: 17 February 2006).

201.Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use.

202.Directive 2010/84/EU of the European Parliament and of the Council of 15

December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC					on
the	Community	code relating to	medicinal products for human use.
[Электронныйресурс].		-	Режим	доступа:

http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN: PDF

203.Directive 2001/83/EC of the European Parliament and of the council of 6 November 2001 on the Community code relating to medicinal products for human use //http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:311:0067:0128:en:PDF

204.Ekman E, Backstrom M. Attitudes among hospital physicians to the reporting of adverse drug reactions in Sweden. Eur J Clin Pharmacol. 2009;65:43–46. doi: 10.1007/s00228-008-0564-9.

205.ЕМЕА, The rules governing medicinal products in the European Union Investigation of Bioavailability and Bioequivalence, v. 3C, 1998, pp. 231-244

206.European Medicines Agency, EMA // URL: http://www.ema.europa.eu

207.European Directorate for the Quality of Medicines & HealthCare//URL: http://www.edqm.eu

208.FDA, Electronic Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations, 20th Edition, 2000

209.Figueiras A, Herdeiro MT, Polonia J, Gestal-Otero JJ. An educational intervention to improve physician reporting of adverse drug reactions: a claster-randomized controlled trial. JAMA.2006; 296:1086-1093.doi:10.1001/jama.296.9.1086.

297

210.Fincham J. A statewide program to stimulate reporting of adverse drug reactions. J Pharm Pract. 1989;2:239–244. doi: 10.1177/089719008900200407.

211.Fitzgerald RJ. Medication errors: the importance of an accurate drug history. Br J Clin Pharmacol 2009; 67: 671–5.

212.Food and Drug Administration // URL: http://www.fda.gov

213.Foster JM, van der Molen T, de Jong-van den Berg L (2007) Patient-reporting of side effects may provide an important source of information in clinical practice. Eur J Clin Pharmacol. 63:979– 980.doi:10.1007/s00228-007-0339-8

214.Ganther JM, Kreling DH.Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc (Wash) 2000;40:378–383.

215.García AJ, Martos F, Leiva F, Sánchez de la Cuesta F. Generic drugs: good or bad? Physician's knowledge of generic drugs and prescribing habits.Pharmacoepidemiol Drug Saf. 2005 May;14(5):341-8.

216.Gavaza P, Brown CM, Lawson KA, Rascati KL, Wilson JP, Steinhardt M. Influence of attitudes on pharmacists' intention to report serious adverse drug events to the Food and Drug Administration. Br J Clin Pharmacol. 2011 Jul;72(1):143-52. doi: 10.1111/j.1365-2125.2011.03944.x.

217.Gedde-Dahl A, Harg P, Stenberg-Nilsen H, Buajordet M, Granas AG, Horn AM.Characteristics and quality of adverse drug reaction reports by pharmacists in Norway.Pharmacoepidemiol Drug Saf. 2007 Sep;16(9):999-1005.

218.Guideline for good clinical practice. ICH Harmonised Tripartite Guideline E6 (R1) // URL: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_ R1/Step4/E6_R1__Guideline.pdf

219.Guidance on the Selection of Comparator Pharmaceutical Product for Equivlence Assessment of Interchangeable Multisourse (Generic) Products. – WHO Technical

Report Series, №902, 2002.

220. Gunderman RB, Phillips MD, Cohen MD. Improving clinical histories on radiology requisitions. Acad Radiol.2001;8(4):299-303. DOI:10.1016/S1076- 6332(03)80498-1.

298

221.Grootheest K, Jong-van den Berg L. Patients' role in reporting adverse drug reactions. Expert Opin Drug Saf. 2004;3:363–368. doi: 10.1517/14740338.3.4.363.

222.ICH Harmonised Tripartite Guideline: Organisation of The Common Technical Document for th Registration of Pharmaceuticals for Human Use. M4. – Geneva: ICH, 2004/URL: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4_R3_Organisati on/M4_R3__organisation.pdf

223.International Conference on Harmonization [Электронныйресурс]. -

Режимдоступа: http://www.ich.org/

224.Hanafi S, Torkamandi H, Hayatshahi A, Gholami K, Shahmirzadi NA, Javadi MR. An educational intervention to improve nurses' knowledge, attitude, and practice toward reporting of adverse drug reactions. Iran J Nurs Midwifery Res. 2014 Jan;19(1):101-6.

225.Hunsel F et al. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J ClinPharmacol. 2010 Nov; 66 (11): 1143 - 1150.

226.Hunsel F, Passier A, Grootheest AC. Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol. 2009;67:558–564. doi: 10.1111/j.1365-2125.2009.03400.x.

227.Hasford J, Goettler M, Munter KH, et al. Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol. 2002;55:945–950. doi: 10.1016/S0895-4356(02)00450-X.

228.Hassali MA, Shafie AA, Jamshed S, Ibrahim MI, Awaisu A. Consumers' views on generic medicines: a review of the literature.Int J Pharm Pract. 2009 Apr;17(2):79-88.

229.Herdeiro M.T., Figueiras A., Polonia J., Gestal-Otero JJ. Influence of pharmacists' attitudes on adverse drug reaction reporting: a case-control study in Portugal. Drug Saf. 2006;29(4):331-40.

230.Inês Ribeiro-Vaz; Maria Teresa Herdeiro; Jorge Polónia; Adolfo

Figueiras.Strategies to increase the sensitivity of pharmacovigilance in Portugal Rev.

Saúde Pública vol.45 n.1 São Paulo Feb. 2011 Epub Nov 12, 2010.

299

231. International Conference on Harmonization //URL: http://www.ich.org/

232.Homoeopathic Pharmacopoeia Convention of the United States //

http://www.hpus.com

233.Homoeopathic Pharmacopoeia Convention of the United States (HPCUS). Procedure Manual, April 2010 Revision 4.2HPCUS Procedure Manual, 2010 (Rev 4.2) // http://www.hpus.com/HPCUS-PM.pdf

234.Jarernsiripornkul N, Krska J, Capps PA, Richards RM, Lee A. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol. 2002 Mar;53(3):318-25.

235.Jarernsiripornkul N, Kakaew W, Loalukkana W, Krska J. Adverse drug reaction monitoring: comparing doctor and patient reporting for new drugs. Pharmacoepidemiol Drug Saf. 2009 Mar;18(3):240-5.

236.Joint Statement between The International Pharmaceutical Federation (FIP) and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA): Ensuring Quality and Safety of Medicinal Products to Protect the Patient. – Geneva: FIP, IFPMA, 2002.

237.Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van Den Anker JNA. Survey of the Use of Off-Label and Unlicensed Drugs in Dutch Childrens Hospital.Pediatrics. 2001;108:1089-1093.

238.Johnston A, Staylas P, Stergiou G. Effectiveness, safety and cost of drug substitution in hypertension. Br J Clin Pharmacol 70: 3; 320-334.

239.Kanavos P. Do generics offer significant savings to the UK National Health Service? Curr Med Res Opin. 2007;23:105–116. doi: 10.1185/030079907X159506.

240.Kazeem A. Oshikoya, Jacob O. Awobusuyi. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria.BMC Clin Pharmacol. 2009;9:14. Published online 2009August 11 doi:10.1186/1472-6904-9-14.

241.Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300:2514–

2526. doi: 10.1001/jama.2008.758

300

242.Khalili H, Mohebbi N, Hendoiee N, Keshtkar AA, Dashti-Khavidaki S. Improvement of knowledge, attitude and perception of healthcare workers about ADR, a preand post-clinical pharmacists' interventional study.BMJ Open. 2012 Jan 13;2:e000367. doi: 10.1136/bmjopen-2011-000367. Print 2012.

243.Langen J, Hunsel F, Passier A, et al. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf. 2008;31:515–524. doi: 10.2165/00002018-200831060-00006.

244.Likic´ R,Maxwell SRJ. Prevention of medication errors: teaching and training. Br J

Clin Pharmacol 2009; 67: 656–61.

245.Lise Aagaard, Ebba Holme Hansen Consumers' reports of suspected adverse drug reactions volunteered to a consumer magazine. Br J Clin Pharmacol. 2010 March; 69(3): 317–318.

246.McGettigan P, Golden J, Conroy RM, Arthur N, Feely J. Reporting of adverse drug reactions by hospital doctors and the response to intervention. Br J Clin Pharmacol. 1997;44:98–100. doi: 10.1046/j.1365-2125.1997.00616.x.

247.Medicines: safety of medicines – adverse drug reactions.FactsheetN°293.UpdatedOctober2008. [Электронный ресурс]. - Режим доступа: http://www.who.int/mediacentre/factsheets/fs293/ru/.

248.MedWatch: The FDA Safety Information and Adverse Event Reporting Program

[Электронныйресурс].	-	Режимдоступа:
http://www.fda.gov/Safety/MedWatch/default.htm

249.MedWatch Consumer Voluntary Reporting [Электронныйресурс]. -

Режимдоступа:

http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM349464.

pdf

250.MedWatch Online Voluntary Reporting Form (3500)// URL: https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm

251.United States Pharmacopeia // URL: http://www.usp.org